Supplementary Material for Pfizer’s Lyme Disease Vaccine Candidate (VLA15) Pipeline
Year: 2025
Type: supplementary-materials
Abstract: Congress materials may include information for investigational products or for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Regulatory approval of investigational products or uses is dependent on the completion of the study programs and review by regulatory authorities. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of February 2025.
Source: Figshare
Author: Fadel, Suki
Language: English
Subfield: Parasitology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W6889093093
Cites:
Cited by:
Related to: